Smidt Heart Institute Proteins Expert Honored With Two Biomedicine Awards

Work of Jennifer Van Eyk, PhD, Centers on How Heart Disease Changes Proteins Found in the Body and How Proteins Differ in Men, Women

Jennifer Van Eyk, PhD, director of the Advanced Clinical Biosystems Research Institute in the Smidt Heart Institute at Cedars-Sinai has been honored by two national organizations for her excellence and leadership in the field of biomedicine: the United States Human Proteome Organization (US HUPO) and Northeastern University’s Barnett Institute.

For more than 25 years, Van Eyk’s work has focused on clinical proteomics, the study of the structure and function of proteins within the body. Her research also is aimed at understanding how disease alters proteins differently in women with heart disease than men with heart disease.

“My team’s mission is to move our discoveries through the science pipeline and into the hands of clinicians to create better outcomes for patients,” said Van Eyk, the Erika J. Glazer Chair in Women’s Heart Health at Cedars-Sinai. “It’s an honor to have our work recognized by these prestigious organizations.”

The proteomics organization awarded Van Eyk the Catherine E. Costello Award for Exemplary Achievements in Proteomics, which recognizes a researcher who has made significant discoveries and accomplished scientific achievements. Van Eyk will be honored at the organization’s annual conference in Portland, Oregon, in March.

Van Eyk also has been awarded the biennial Karger Medal from the Barnett Institute at Northeastern University for her outstanding achievements in bioanalytical chemistry.

“Dr. Van Eyk is an international leader in this field,” said Eduardo Marbán, MD, PhD, executive director of the Smidt Heart Institute. “The discoveries coming out of her lab are changing the face of medicine. She richly deserves every recognition for her outstanding work.”

During 2023, Van Eyk’s work has received an abundance of honors. Earlier this year, Van Eyk also was recognized with the Distinguished Contribution Award from the Association for Mass Spectrometry and Advances in the Clinical Lab, the President’s Distinguished Lecture Award from the International Society for Heart Research, and a spot on the 2023 Ten Years of Impact Power List by The Analytical Scientist. Most recently, her research lab was included on first lady Jill Biden’s tour of Cedars-Sinai women’s health research.

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version